lexapro has been researched along with orlistat in 1 studies
| Studies (lexapro) | Trials (lexapro) | Recent Studies (post-2010) (lexapro) | Studies (orlistat) | Trials (orlistat) | Recent Studies (post-2010) (orlistat) |
|---|---|---|---|---|---|
| 17 | 0 | 12 | 1,432 | 274 | 539 |
| Protein | Taxonomy | lexapro (IC50) | orlistat (IC50) |
|---|---|---|---|
| Phosphatidylserine lipase ABHD16A | Homo sapiens (human) | 0.1 | |
| Pancreatic triacylglycerol lipase | Sus scrofa (pig) | 0.4214 | |
| Lipoprotein lipase | Homo sapiens (human) | 0.066 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.42 | |
| Hepatic triacylglycerol lipase | Homo sapiens (human) | 0.003 | |
| Pancreatic triacylglycerol lipase | Homo sapiens (human) | 0.3253 | |
| Translocator protein | Rattus norvegicus (Norway rat) | 1 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.42 | |
| Kappa-type opioid receptor | Mus musculus (house mouse) | 0.1903 | |
| Fatty acid synthase | Homo sapiens (human) | 2.99 | |
| Fatty-acid amide hydrolase 1 | Rattus norvegicus (Norway rat) | 0.01 | |
| Platelet-activating factor acetylhydrolase | Homo sapiens (human) | 0.05 | |
| Diacylglycerol lipase-alpha | Mus musculus (house mouse) | 0.02 | |
| Lysophosphatidylserine lipase ABHD12 | Homo sapiens (human) | 0.1682 | |
| Diacylglycerol lipase-beta | Homo sapiens (human) | 0.24 | |
| Monoacylglycerol lipase ABHD6 | Homo sapiens (human) | 0.03 | |
| Acyl-protein thioesterase 2 | Rattus norvegicus (Norway rat) | 0.17 | |
| Diacylglycerol lipase-alpha | Homo sapiens (human) | 0.2677 | |
| Endothelial lipase | Homo sapiens (human) | 0.006 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
1 other study(ies) available for lexapro and orlistat
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |